Stock AnalizSepterna, Inc. SEPN
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Septerna, Inc. (SEPN) is a healthcare company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $96M and net income of -$59M, a net margin of -61.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -16%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $96M | $46M | $1M | — |
| Net income | -$59M | -$49M | -$72M | $4M |
| Free cash flow | -$78M | $110M | -$70M | -$42M |
| EPS (diluted) | $-1.29 | $-1.10 | $-7.26 | $0.29 |
| Net margin | -61.3% | -106.4% | -6678.9% | — |
| ROIC | — | -13.3% | -18.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $59.22, 39% above the current price; targets range from $48.00 to $65.00; the consensus rating is “Strong buy”; expected EPS is $-1.35 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Septerna pay a dividend?
Not currently.
Is Septerna a good stock to buy?
We do not give buy or sell advice. Septerna scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.